-
Net Sales are expected to increase by 24 percent Y-o-Y (up 0.8 percent Q-o-Q) to Rs 5,050.3 crore, according to Nirmal Bang.
-
Net Sales are expected to decrease by 1.8 percent Y-o-Y (up 2.3 percent Q-o-Q) to Rs 3,953.9 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to decrease by 0.2 percent Y-o-Y (up 0.1 percent Q-o-Q) to Rs 3,788.1 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to decrease by 3.5 percent Y-o-Y (down 8.4 percent Q-o-Q) to Rs 3,685.8 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to increase by 8.7 percent Y-o-Y (up 5.4 percent Q-o-Q) to Rs 3,956 crore, according to KRChoksey.
-
Net Sales are expected to increase by 5.4 percent Y-o-Y (down 0.3 percent Q-o-Q) to Rs 3,836.2 crore, according to ICICI Direct.
-
Net Sales are expected to increase by 2.5 percent Y-o-Y (up 1.3 percent Q-o-Q) to Rs. 3,844 crore, according to Sharekhan.
-
Net Sales are expected to increase by 5.3 percent Y-o-Y (up 0.3 percent Q-o-Q) to Rs. 3,638.1 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to increase by 17.4 percent Y-o-Y (down 0.6 percent Q-o-Q) to Rs. 3,475.2 crore, according to Emkay.
-
Net Sales are expected to increase by 13.9 percent Y-o-Y (down 11.7 percent Q-o-Q) to Rs. 3,296.1 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to decrease by 3.6 percent Y-o-Y (down 12.4 percent Q-o-Q) to Rs. 3,134.8 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to decrease by 6.7 percent Y-o-Y (up 2.8 percent Q-o-Q) to Rs. 3,043 crore, according to Sharekhan.
-
Net Sales are expected to decrease by 1.1 percent Y-o-Y (up 8.8 percent Q-o-Q) to Rs. 3,222.2 crore, according to ICICI Direct.
-
For Lupin, Credit Suisse sees margin improving but weak Tamiflu season could be an overhang.
-
Net Sales are expected to decrease by 5.2 percent Y-o-Y (up 5.9 percent Q-o-Q) to Rs. 3,070 crore, according to HDFC Securities.
-
Net Sales are expected to decrease by 4.4 percent Y-o-Y (up 8.1 percent Q-o-Q) to Rs. 3,093 crore, according to Sharekhan.
-
Net Sales are expected to decrease by 7.6 percent Y-o-Y (up 3.2 percent Q-o-Q) to Rs. 2,986.6 crore, according to ICICI Direct.
-
"For the first time after six consecutive quarters, the pharma companies under our coverage will report double digit YoY growth of 13 percent in revenues,” said HDFC Securities
-
Global brokerage houses have upgraded a few stocks, highlighting robust Q4 FY18 results. Moneycontrol takes a look at six such stocks which have seen a ratings upgrade
-
Net Sales are expected to increase by 24 percent Y-o-Y (down 5.7 percent Q-o-Q) to Rs. 3,070 crore, according to HDFC Securities.
-
Net Sales are expected to increase by 27.7 percent Y-o-Y (down 2.9 percent Q-o-Q) to Rs. 3,163.5 crore, according to Edelweiss.
-
Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.
-
As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.
-
The USFDA granted 246 nods in Q3FY18, which is the highest-ever approvals in a single quarter. Cadila Healthcare received 23 and Aurobindo Pharma got 18 approvals.
-
Net Sales are expected to increase by 5.8 percent Q-o-Q (down 0.4 percent Y-o-Y) to Rs 2434.2 crore, according to ICICI Securities. Cadila to report net profit at 309.7 crore up 19.5% quarter-on-quarter.
